- Home
- CNTX vs RGLS Comparison
CNTX vs RGLS Comparison
Compare CNTX & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- RGLS
- Stock Information
- Founded
- CNTX 2015
- RGLS 2007
- Country
- CNTX United States
- RGLS United States
- Employees
- CNTX N/A
- RGLS N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- RGLS Health Care
- Exchange
- CNTX Nasdaq
- RGLS Nasdaq
- Market Cap
- CNTX 67.7M
- RGLS 74.0M
- IPO Year
- CNTX 2021
- RGLS 2012
- Fundamental
- Price
- CNTX $0.81
- RGLS $1.31
- Analyst Decision
- CNTX Strong Buy
- RGLS Strong Buy
- Analyst Count
- CNTX 5
- RGLS 6
- Target Price
- CNTX $6.70
- RGLS $10.33
- AVG Volume (30 Days)
- CNTX 147.9K
- RGLS 815.2K
- Earning Date
- CNTX 03-20-2025
- RGLS 03-20-2025
- Dividend Yield
- CNTX N/A
- RGLS N/A
- EPS Growth
- CNTX N/A
- RGLS N/A
- EPS
- CNTX N/A
- RGLS N/A
- Revenue
- CNTX N/A
- RGLS N/A
- Revenue This Year
- CNTX N/A
- RGLS N/A
- Revenue Next Year
- CNTX N/A
- RGLS N/A
- P/E Ratio
- CNTX N/A
- RGLS N/A
- Revenue Growth
- CNTX N/A
- RGLS N/A
- 52 Week Low
- CNTX $0.77
- RGLS $0.83
- 52 Week High
- CNTX $2.75
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- CNTX 39.82
- RGLS 53.78
- Support Level
- CNTX $0.77
- RGLS $1.22
- Resistance Level
- CNTX $0.87
- RGLS $1.60
- Average True Range (ATR)
- CNTX 0.08
- RGLS 0.13
- MACD
- CNTX 0.01
- RGLS 0.03
- Stochastic Oscillator
- CNTX 20.75
- RGLS 50.85
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.